Adherence to Guidelines in Heart Failure, Is It Valid for Elderly Patients?

Area of Science:

• Cardiology
• Geriatric Medicine
• Pharmacology

Background:

• Current heart failure with reduced ejection fraction (HFrEF) treatment guidelines are based on studies that largely excluded older adults.
• This underrepresentation limits the applicability of existing evidence-based therapies to the geriatric population.

Purpose of the Study:

• To evaluate the effectiveness of guideline-directed medical therapy (GDMT) in patients aged 80 years and older diagnosed with HFrEF.
• To compare outcomes between GDMT and personalized medicine approaches in this specific demographic.

Main Methods:

• A retrospective analysis of 254 HFrEF patients aged 80+ hospitalized with acute decompensated heart failure (ADHF).
• Patients were categorized into GDMT (≥2 guideline-recommended drugs) or personalized medicine (≤1 drug) groups at discharge.
• Primary outcomes included 90-day all-cause mortality, 90-day rehospitalization, and 3-year mortality.

Main Results:

• No statistically significant differences were observed in 90-day mortality (17% vs. 13%, P=0.169) between GDMT and personalized medicine groups.
• Similarly, 90-day rehospitalization rates (51% vs. 45.6%, P=0.27) and 3-year mortality (64.5% vs. 63.3%, P=0.915) did not differ significantly.
• The study included 1152 HFrEF patients, with 254 (22%) being 80 years or older.

Conclusions:

• Adherence to current HFrEF treatment guidelines may not yield the same benefits in older adults (80+) as observed in younger populations from randomized trials.
• Further large-scale prospective research is necessary to establish optimal treatment strategies for elderly HFrEF patients.